Paratek Pharmaceuticals (NASDAQ:PRTK) Trading Up 2.4%

Paratek Pharmaceuticals Inc (NASDAQ:PRTK)’s stock price was up 2.4% during mid-day trading on Thursday . The company traded as high as $4.40 and last traded at $4.27, approximately 36,269 shares were traded during trading. A decline of 86% from the average daily volume of 255,210 shares. The stock had previously closed at $4.17.

A number of research analysts recently issued reports on PRTK shares. Wedbush restated an “outperform” rating and set a $12.00 price target (down previously from $17.00) on shares of Paratek Pharmaceuticals in a report on Thursday, May 9th. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating and set a $4.75 price target on the stock in a report on Friday. ValuEngine upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Wednesday, June 26th. Finally, LADENBURG THALM/SH SH restated a “buy” rating on shares of Paratek Pharmaceuticals in a report on Thursday, May 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. Paratek Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $17.25.

The stock’s 50-day moving average is $3.61. The company has a quick ratio of 13.95, a current ratio of 12.17 and a debt-to-equity ratio of 14.48.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.16) by $0.14. The business had revenue of $2.05 million for the quarter, compared to analysts’ expectations of $1.86 million. Paratek Pharmaceuticals had a negative return on equity of 459.96% and a negative net margin of 597.22%. Equities analysts predict that Paratek Pharmaceuticals Inc will post -4.32 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its position in Paratek Pharmaceuticals by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 138,282 shares of the specialty pharmaceutical company’s stock valued at $710,000 after acquiring an additional 1,906 shares in the last quarter. Teton Advisors Inc. boosted its position in Paratek Pharmaceuticals by 1.9% during the 1st quarter. Teton Advisors Inc. now owns 110,000 shares of the specialty pharmaceutical company’s stock valued at $590,000 after acquiring an additional 2,000 shares in the last quarter. General American Investors Co. Inc. boosted its position in Paratek Pharmaceuticals by 1.1% during the 2nd quarter. General American Investors Co. Inc. now owns 470,185 shares of the specialty pharmaceutical company’s stock valued at $1,876,000 after acquiring an additional 5,200 shares in the last quarter. Bank of Montreal Can boosted its position in Paratek Pharmaceuticals by 503.1% during the 2nd quarter. Bank of Montreal Can now owns 7,816 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 6,520 shares in the last quarter. Finally, BNP Paribas Arbitrage SA bought a new stake in Paratek Pharmaceuticals during the 1st quarter valued at approximately $36,000. 75.00% of the stock is currently owned by institutional investors and hedge funds.

About Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Recommended Story: Risk Tolerance

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.